GOSS News and Press, Gossamer Bio Inc. From 12/03/19

BeyondSpring (NASDAQ: BYSI ) initiated with Market Perform rating at Oppenheimer. More news on: BeyondSpring Inc., Centogene N.V., Curaleaf Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that members of the management team will participate in...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Seth Klarman’s Baupost Group Holdings...

Gossamer Bio, Inc . (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and...

Image source: The Motley Fool. Gossamer Bio Inc   (NASDAQ: GOSS) Q3 2019 Earnings Call Nov 12, 2019 , 4:30 p.m. ET Operator Continue reading

Gossamer Bio, Inc. (GOSS) Q3 2019 Earnings Conference Call November 12, 2019 04:30 PM ET Company Participants Bryan Giraudo - Chief Financial Officer Sheila Gujrathi - Co-founder & Chief Executive Officer Jakob Dupont - Chief Medical Officer Luisa Salter-Cid - Chief Scienti...

Gossamer Bio (NASDAQ: GOSS ): Q3 GAAP EPS of -$0.80 misses by $0.11 . More news on: Gossamer Bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

– Clinical programs on track for multiple topline data releases in 2020 – – Entered clinical trial collaboration with Merck to evaluate KEYTRUDA ® (pembrolizumab) in combination with GB1275 in advanced solid tumors – – Company to host confe...